# A Clinical Trial Evaluating TG4050 in Head and Neck Cancer

Source: https://onco.cc/trials/nct04183166/  
OnCo record `nct04183166` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TG4050 in head and neck squamous cell carcinoma, run by Transgene, active and no longer recruiting.

## Summary

A Clinical Trial Evaluating TG4050 in Head and Neck Cancer is a phase 1/2 interventional study registered as NCT04183166 by Transgene, with 80 participants enrolled, started 2019-12-12 and due to reach its primary completion in 2027-12-30. Interventions recorded: TG4050.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04183166
- Phase: 1/2
- Setting: A Randomized Phase I/II Trial in Patients With Newly Diagnosed, Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Evaluating a Mutanome-directed Immunotherapy.
- Sponsor: Transgene
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT04183166: https://clinicaltrials.gov/study/NCT04183166

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- companies: [Transgene](https://onco.cc/companies/transgene/)

---
JSON: https://onco.cc/api/v1/entities/nct04183166.json